

Investigating The Contribution of Residual Unexplained Variability Components in NLME Approach

Mutaz M. Jaber, PharmD
jaber038@umn.edu

PhD student, Dept. of Experimental and Clinical pharmacology

Nov. 24, 2021

Clinical trial simulation is gaining much attention in this decade

Clinical trials are going toward simulation to reduce cost and making space for predictive models.

Two levels of random effects in NLME approach: Between-subject and Residual-unexplained variability

$$\eta_i \sim \mathcal{N}(0, \omega^2) \quad (1)$$

$$\epsilon_j \sim \mathcal{N}(0, \sigma^2) \quad (2)$$

Residuals are the left-over from the modeling cake